PL365291A1 - Zastosowanie długiej pentraksyny PTX3 do otrzymywania leku zapobiegającego i leczącego zaburzenia autoimmunologiczne - Google Patents

Zastosowanie długiej pentraksyny PTX3 do otrzymywania leku zapobiegającego i leczącego zaburzenia autoimmunologiczne

Info

Publication number
PL365291A1
PL365291A1 PL01365291A PL36529101A PL365291A1 PL 365291 A1 PL365291 A1 PL 365291A1 PL 01365291 A PL01365291 A PL 01365291A PL 36529101 A PL36529101 A PL 36529101A PL 365291 A1 PL365291 A1 PL 365291A1
Authority
PL
Poland
Prior art keywords
cure
medicament
prevention
preparation
autoimmune pathologies
Prior art date
Application number
PL01365291A
Other languages
English (en)
Inventor
Alberto Mantovani
Barbara Bottazzi
Giuseppe Peri
Angelo Manfredi
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of PL365291A1 publication Critical patent/PL365291A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL01365291A 2000-11-03 2001-10-18 Zastosowanie długiej pentraksyny PTX3 do otrzymywania leku zapobiegającego i leczącego zaburzenia autoimmunologiczne PL365291A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000RM000571A IT1317927B1 (it) 2000-11-03 2000-11-03 Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
PCT/IT2001/000530 WO2002036151A2 (en) 2000-11-03 2001-10-18 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies

Publications (1)

Publication Number Publication Date
PL365291A1 true PL365291A1 (pl) 2004-12-27

Family

ID=11454977

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365291A PL365291A1 (pl) 2000-11-03 2001-10-18 Zastosowanie długiej pentraksyny PTX3 do otrzymywania leku zapobiegającego i leczącego zaburzenia autoimmunologiczne

Country Status (19)

Country Link
US (1) US20040029803A1 (pl)
EP (1) EP1370279B1 (pl)
JP (1) JP4105542B2 (pl)
KR (1) KR100812805B1 (pl)
CN (1) CN1326563C (pl)
AT (1) ATE303819T1 (pl)
AU (2) AU1518902A (pl)
BR (1) BR0115050A (pl)
CA (1) CA2427533A1 (pl)
CZ (1) CZ297242B6 (pl)
DE (1) DE60113304T2 (pl)
DK (1) DK1370279T3 (pl)
ES (1) ES2248401T3 (pl)
HU (1) HUP0401593A2 (pl)
IT (1) IT1317927B1 (pl)
MX (1) MXPA03003805A (pl)
PL (1) PL365291A1 (pl)
SK (1) SK5332003A3 (pl)
WO (1) WO2002036151A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
EP1599226B1 (en) * 2003-02-21 2012-09-19 Medvet Science Pty. Ltd. A method of diagnosis and treatment
ITRM20030595A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso della ptx3 o di un suo derivato funzionale da sola o in associazione con tsg6 per il trattamento di patologie degenarative dell'osso o della cartilagine e per il trattamento della infertilita' femminile.
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
ITRM20040489A1 (it) * 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
US8337828B2 (en) 2006-05-02 2012-12-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection
KR101305515B1 (ko) 2011-06-10 2013-09-06 경북대학교 산학협력단 펜트락신 3 단백질의 파킨슨 질환 진단 용도
US20150299277A1 (en) * 2012-06-22 2015-10-22 The University Of Tokyo Agent for treating or preventing systemic inflammatory response syndrome
CN105903001A (zh) * 2016-05-09 2016-08-31 中国科学院海洋研究所 一种鱼类穿透素的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
US6013217A (en) * 1997-12-22 2000-01-11 Dow Corning Corporation Method for extruding thermoplastic resins

Also Published As

Publication number Publication date
SK5332003A3 (en) 2003-12-02
CN1326563C (zh) 2007-07-18
WO2002036151A2 (en) 2002-05-10
HK1071291A1 (en) 2005-07-15
ATE303819T1 (de) 2005-09-15
CN1561226A (zh) 2005-01-05
CA2427533A1 (en) 2002-05-10
AU1518902A (en) 2002-05-15
JP2004512372A (ja) 2004-04-22
WO2002036151A3 (en) 2003-10-16
US20040029803A1 (en) 2004-02-12
HUP0401593A2 (hu) 2004-12-28
CZ297242B6 (cs) 2006-10-11
EP1370279B1 (en) 2005-09-07
KR20030060918A (ko) 2003-07-16
DE60113304T2 (de) 2006-06-08
CZ20031043A3 (cs) 2003-09-17
ITRM20000571A1 (it) 2002-05-03
JP4105542B2 (ja) 2008-06-25
AU2002215189B2 (en) 2006-08-03
DK1370279T3 (da) 2006-01-23
EP1370279A2 (en) 2003-12-17
ITRM20000571A0 (it) 2000-11-03
KR100812805B1 (ko) 2008-03-12
IT1317927B1 (it) 2003-07-15
DE60113304D1 (de) 2005-10-13
ES2248401T3 (es) 2006-03-16
MXPA03003805A (es) 2004-04-20
BR0115050A (pt) 2003-09-30

Similar Documents

Publication Publication Date Title
GB0123381D0 (en) Factor
AU3699197A (en) Polynucleotide vaccine formula against porcine reproductive and respiratory pathologies
IL202633A0 (en) Sulfonamide derivatives and pharmaceutical compositions containing the same
IL141403A0 (en) Deleted adenoviruses and methods of making and administering the same
AU1518902A (en) Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies
MY129572A (en) Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor
ZA981780B (en) The use of levobupivacaine in paediatric surgery
PT1164996E (pt) Sistemas terapeuticos transdermicos com nicotina e adicao de cetonas monoterpenicas
AU2251302A (en) Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
AU2001247008A1 (en) Variants of the human amp-activated protein kinase gamma 3 subunit
AP2000001950A0 (en) Paroxetine maleate.
EP1275657A4 (en) PEPTIDE DERIVATIVES AND MEDICINAL COMPOSITIONS
MD980129A (en) Antiherpetic remedy
Umland Vladimir Zhirinovskii in Russian politics: three approaches to the emergence of the Liberal-Democratic Party of Russia 1990-1993
PL357906A1 (pl) Środki przeciwnadciśnieniowe i ich zastosowanie
EP1253113A4 (en) NOVEL AQUEOUS COMPOSITIONS AND USE THEREOF
AU4847400A (en) A-form of cytoplasmic domain of naria (crd-neuregulin) and uses thereof
ZA200103250B (en) The treatment of immunomodulatory related and other diseases or conditions.
WO1999015160A3 (en) Use of 6,7-substituted 2-aminotetralines suitable for preparing pharmaceutical composition for the therapeutic treatment of inflammatory and/or autoimmune pathologies
ZA995006B (en) Pharmaceutical composition of hedgehog proteins and use thereof.
MD1195F1 (en) Hemotherapy remedy
AU2001285141A1 (en) Human carboxylesterase family member and uses thereof
ITVR970055A0 (it) Dispositivi per operare chirurgicamente sulle vertebre e altre parti del corpo
AU2001245370A1 (en) Novel human transferase proteins and polynucleotides encoding the same
YU40098A (sh) Upotreba olanzapina za dobijanje leka